# First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

> **NCT01524991** · PHASE2 · COMPLETED · sponsor: **Hoosier Cancer Research Network** · enrollment: 36 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01524991
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2017-07-15
- **Final completion:** 2018-12-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524991, "First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01524991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*